Johnson & Johnson (JNJ) to Release Quarterly Earnings on Wednesday

Johnson & Johnson (NYSE:JNJ - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Wednesday, July 16th. Analysts expect Johnson & Johnson to post earnings of $2.65 per share and revenue of $22.85 billion for the quarter. Johnson & Johnson has set its FY 2025 guidance at 10.500-10.700 EPS.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. On average, analysts expect Johnson & Johnson to post $11 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ traded up $2.69 during trading hours on Thursday, reaching $158.97. The stock had a trading volume of 1,667,076 shares, compared to its average volume of 8,991,483. The business's fifty day moving average is $153.67 and its two-hundred day moving average is $154.27. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The company has a market cap of $382.50 billion, a price-to-earnings ratio of 17.68, a PEG ratio of 2.36 and a beta of 0.41. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a dividend of $1.30 per share. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.27%. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is currently 57.84%.

Hedge Funds Weigh In On Johnson & Johnson

A hedge fund recently raised its stake in Johnson & Johnson stock. Brighton Jones LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 13.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 51,876 shares of the company's stock after buying an additional 6,332 shares during the quarter. Brighton Jones LLC's holdings in Johnson & Johnson were worth $7,502,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

JNJ has been the subject of several recent analyst reports. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Finally, Barclays dropped their target price on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Eleven research analysts have rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.